Home/Healthcare/Drug Pipeline/Global Wearable Injectors Market

Global Wearable Injectors Market - Strategic Insights and Forecasts (2026-2031)

Market Analysis, Growth, Trends & Forecast By Type (On-Body Injectors, Off-Body Injectors), By Technology (Motor-driven, Expanding Battery, Spring-based, Rotary Pump, Others), By Application (Oncology, Diabetes, Cardiovascular Disease, Autoimmune Disease, Others), By End-User (Hospitals and Clinics, Ambulatory Surgery Centres, Home Care Centres, Other), and Geography

$3,950
Single User License

Report Overview

The global wearable injectors market is forecast to grow at a CAGR of 19.7%, reaching USD 29.9 billion in 2031 from USD 12.2 billion in 2026.

Market Growth Projection (CAGR: 19.7%)
$12.20B
2026
$14.60B
2027
$29.90B
2031
Global Wearable Injectors Market Highlights
Wearable injectors are delivering high-volume, viscous drugs at controlled intervals for chronic disease management.
Patients are self-administering medications easily, reducing hospital visits and needlestick injuries.
Technological advancements are lowering manufacturing costs and improving dose accuracy.
Companies are partnering to develop innovative, patient-friendly enFuse® and Omnipod® systems.

Wearable injectors are medical devices used for drug delivery systems. It is attached to the patient to deliver the drugs in a controlled manner. For the same reason, the devices are also called patch pumps or patch injectors.  These devices are typically used for high-volume medications, drugs with high viscosities, and medicines that are required at regular intervals over a long period. The device reduces the need for multiple painful injections, making it convenient and user-friendly.

Wearable injectors are easy to use, especially when regular intervals of medication are required, thus providing a significant advantage over manual injections. The growing prevalence of chronic diseases and changing lifestyles around the globe are considered the key drivers for the global wearable injector market growth.

The wearable injectors are user-friendly, making them easy to self-administer. They also do not interfere with the user's day-to-day life.  These devices improve dose accuracy and prevent needlestick injuries. Furthermore, rising healthcare costs and changes in technology have led to innovative solutions that are efficient for managing the disease and also reduce the number of trips to hospitals and clinics to receive medical support for an injection.

Wearable Injectors Market Growth Drivers:

  • Increasing number of chronic diseases and lifestyle changes is anticipated in the market growth.

Chronic or non-communicable diseases like cancer, hypertension, diabetes, cardiovascular diseases, etc., are the leading causes of death globally. According to the World Health Organisation (WHO), 71% of all deaths are due to non-communicable diseases (NCDs). Globally, 17.9 million people are diseased due to cardiovascular disease annually. This is followed by cancer, respiratory diseases, and diabetes, accounting for 9.3 million, 4.1 million, and 1.5 million deaths, respectively.

Wearable injectors play an important role in managing non-communicable diseases like cardiovascular disease, cancer, diabetes, and autoimmune disease, amongst other diseases. In particular, with the growing sedentary lifestyle. These injectors are highly used devices to deliver drugs prescribed by the doctor at regular intervals. This eliminates the possibility of the drug being over- or underdosed. Not only is it user-friendly, but it also saves time and money by reducing the number of trips to hospitals for medical assistance for injections.

  • Technological advancement and increasing awareness are anticipated in the market growth.

With the increase in awareness of health, precautionary measures, and increased research and development in the medical industry, solutions like wearable injectors play an important role in assisting with various non-communicable diseases. As individuals are becoming more health-conscious, they are not just becoming aware of diseases but of all the alternative treatments and medical devices that are available for the management of such diseases.  

Wearable infusion pumps are lightweight, compact devices that patients wear on their belts with an attached cannula on their skin. These off-body injectors are ideal for patients requiring continuous or intermittent infusions over an extended period, allowing them to move freely during treatment. Most insulin pumps are worn on the belt, connected to the infusion set in subcutaneous fatty tissue.

Several steps are taken by governments and international organizations to raise awareness amongst the citizens to ensure that timely assistance is provided. Further, with technological advancement, the manufacturing cost has been reduced significantly. By using highly advanced automation, companies can reach economies of scale. Increasing profits and focusing more on R&D for better solutions are also priorities.

Wearable Injectors Market Restraints:

  • Environmental concerns could hamper the market growth.

Though wearable injectors are life-saving devices, they come at a cost to the environment. These devices are made of plastic bodies and are manufactured for one-time use purposes. Mishandling of devices and their improper disposal can also be hazardous.  Since these devices need proper disposal and not all countries have a good disposal system, this not only affects other humans but also the ecosystem, as plastic takes a long time to decompose.

Wearable Injectors Market Key Developments:

  • April 2026: Modular Medical received FDA 510(k) clearance for the Pivot™ tubeless insulin patch pump, featuring a removable two-part wearable injector design for insulin-dependent diabetes patients.

  • February 2026: Insulet Corporation launched the Omnipod® 5 automated insulin delivery system and Omnipod Discover™ platform across Middle Eastern markets, expanding wearable insulin management solutions.

  • November 2025: Modular Medical, Inc. submitted its Pivot™ tubeless insulin patch pump for FDA 510(k) clearance, targeting simplified wearable insulin delivery for diabetes management.

  • August 2025: Enable Injections received ANVISA approval in Brazil and MHRA registration in the UK for its enFuse® on-body wearable drug delivery system platform.

  • July 2025: BD (Becton, Dickinson and Company) announced the first pharma-sponsored clinical trial using the BD Libertas™ wearable injector platform for subcutaneous biologic drug delivery applications.

  • June 2025: Sanofi presented positive Phase 3 IRAKLIA data supporting subcutaneous Sarclisa administration using Enable Injections’ enFuse® wearable on-body injector for multiple myeloma treatment.

List of Top Wearable Injectors Companies:

  • Medtronic

  • Amgen (Acquired by tenebio)

  • Ypsomed

  • Insulet Corporation

  • West Pharmaceutical Services

Wearable Injectors Market Scope:

Report Metric Details
Total Market Size in 2026 USD 12.2 billion
Total Market Size in 2031 USD 29.9 billion
Forecast Unit Billion
Growth Rate 19.7%
Study Period 2021 to 2031
Historical Data 2021 to 2024
Base Year 2025
Forecast Period 2026 – 2031
Segmentation Type, Technology, Application, Geography
Geographical Segmentation North America, South America, Europe, Middle East and Africa, Asia Pacific
Companies
  • Medtronic
  • Amgen (Acquired by tenebio)
  • Ypsomed
  • Insulet Corporation
  • West Pharmaceutical Services

Market Segmentation

By Type

On-Body Injectors
Off-Body Injectors

By Technology

Motor-driven
Expanding Battery
Spring-based
Rotary Pump
Others

By Application

Oncology
Diabetes
Cardiovascular Disease
Autoimmune Disease
Others

By End-user

Hospitals and Clinics
Ambulatory Surgery Centres
Home Care Centres
Other

By Geography

North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
China
India
Japan
South Korea
Indonesia
Thailand
Others

Table of Contents

1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
    2.1. MARKET OVERVIEW
    2.2. MARKET DEFINITION
    2.3. SCOPE OF THE STUDY
    2.4. MARKET SEGMENTATION
3. BUSINESS LANDSCAPE
    3.1. MARKET DRIVERS
    3.2. MARKET RESTRAINTS
    3.3. MARKET OPPORTUNITIES
    3.4. PORTER’S FIVE FORCES ANALYSIS
    3.5. INDUSTRY VALUE CHAIN ANALYSIS
    3.6. POLICIES AND REGULATIONS
    3.7. STRATEGIC RECOMMENDATIONS
4. TECHNOLOGICAL OUTLOOK
5. GLOBAL WEARABLE INJECTORS MARKET BY TYPE
    5.1. INTRODUCTION
    5.2. ON-BODY INJECTORS
    5.3. OFF-BODY INJECTORS
6. GLOBAL WEARABLE INJECTORS MARKET BY TECHNOLOGY
    6.1. INTRODUCTION
    6.2. MOTOR-DRIVEN
    6.3. EXPANDING BATTERY
    6.4. SPRING-BASED
    6.5. ROTARY PUMP
    6.6. OTHERS
7. GLOBAL WEARABLE INJECTORS MARKET BY APPLICATION
    7.1. INTRODUCTION
    7.2. ONCOLOGY
    7.3. DIABETES
    7.4. CARDIOVASCULAR DISEASE
    7.5. AUTOIMMUNE DISEASE
    7.6. OTHERS
8. GLOBAL WEARABLE INJECTORS MARKET BY END-USER
    8.1. INTRODUCTION
    8.2. HOSPITALS AND CLINICS
    8.3. AMBULATORY SURGERY CENTRES
    8.4. HOME CARE CENTRES
    8.5. OTHER
9. GLOBAL WEARABLE INJECTORS MARKET BY GEOGRAPHY
    9.1. INTRODUCTION
    9.2. NORTH AMERICA
        9.2.1. USA
        9.2.2. CANADA
        9.2.3. MEXICO
    9.3. SOUTH AMERICA
        9.3.1. BRAZIL
        9.3.2. ARGENTINA
        9.3.3. OTHERS
    9.4. EUROPE
        9.4.1. GERMANY
        9.4.2. FRANCE
        9.4.3. UNITED KINGDOM
        9.4.4. SPAIN
        9.4.5. OTHERS
    9.5. MIDDLE EAST AND AFRICA
        9.5.1. SAUDI ARABIA
        9.5.2. UAE
        9.5.3. OTHERS
    9.6. ASIA PACIFIC
        9.6.1. CHINA
        9.6.2. INDIA
        9.6.3. JAPAN
        9.6.4. SOUTH KOREA
        9.6.5. INDONESIA
        9.6.6. THAILAND
        9.6.7. OTHERS
10. COMPETITIVE ENVIRONMENT AND ANALYSIS
    10.1. MAJOR PLAYERS AND STRATEGY ANALYSIS
    10.2. MARKET SHARE ANALYSIS
    10.3. MERGERS, ACQUISITIONS, AGREEMENTS, AND COLLABORATIONS
    10.4. COMPETITIVE DASHBOARD
11. COMPANY PROFILES
    11.1. MEDTRONIC
    11.2. AMGEN (ACQUIRED BY TENEBIO)
    11.3. YPSOMED
    11.4. INSULET CORPORATION
    11.5. WEST PHARMACEUTICAL SERVICES
    11.6. BECTON DICKINSON AND COMPANY
    11.7. ENABLE INJECTIONS
    11.8. UNITED THERAPEUTICS CORPORATION
    11.9. F. HOFFMANN-LA ROCHE AG
    11.10. JOHNSON & JOHNSON
12. APPENDIX
    12.1. CURRENCY
    12.2. ASSUMPTIONS
    12.3. BASE AND FORECAST YEARS TIMELINE
    12.4. KEY BENEFITS FOR THE STAKEHOLDERS
    12.5. RESEARCH METHODOLOGY
    12.6. ABBREVIATIONS
LIST OF FIGURES
LIST OF TABLES

Request Customization

Tell us your specific requirements and we will customize this report for you.

📞

Your data is secure. We do not share information with any third party.

Download Free Sample

Get a sample copy of this report with charts, TOC, and methodology.

📞

Your data is secure. We do not share information with any third party.

Speak to Analyst

Ask our analysts any questions you have about this market research report.

📞

Your data is secure. We do not share information with any third party.

Global Wearable Injectors Market Report

Report IDKSI061611830
PublishedApr 2026
Pages153
FormatPDF, Excel, PPT, Dashboard

Need Assistance?

Our research team is available to answer your questions.

Contact Us
Frequently Asked Questions

The global wearable injectors market is forecast for significant growth, projected to reach USD 29.9 billion by 2031, up from USD 12.2 billion in 2026. This expansion represents a robust Compound Annual Growth Rate (CAGR) of 19.7% over the forecast period, highlighting the rapid adoption and increasing demand for these advanced drug delivery systems.

The demand for wearable injectors is primarily driven by the increasing prevalence of chronic diseases and non-communicable diseases (NCDs) such as cardiovascular disease, cancer, diabetes, and autoimmune conditions. These devices play a crucial role by enabling patients to self-administer high-volume, viscous drugs at controlled intervals, thereby reducing the need for multiple painful injections and frequent hospital visits.

The global market growth is primarily fueled by the increasing prevalence of chronic diseases and changing lifestyles worldwide. Additionally, rising healthcare costs, continuous technological advancements, and the user-friendly nature of wearable injectors that enable easy self-administration and improve dose accuracy are significant drivers, reducing the overall burden on healthcare systems.

Technological advancements are profoundly shaping the competitive landscape by lowering manufacturing costs and improving dose accuracy, making wearable injectors more efficient and accessible. Furthermore, companies are engaging in strategic partnerships to develop innovative, patient-friendly systems like enFuse® and Omnipod®, indicating a strong focus on continuous innovation and enhanced user experience within the market.

Wearable injectors offer significant strategic advantages for future chronic disease management by enabling easy patient self-administration of high-volume, viscous drugs at controlled intervals. They improve dose accuracy, prevent needlestick injuries, and reduce the need for frequent hospital or clinic visits, thus enhancing patient convenience, adherence, and potentially lowering overall healthcare costs associated with long-term care for NCDs.

For patients, wearable injectors offer convenience through easy self-administration, reduced pain from multiple injections, improved dose accuracy, and minimal interference with daily life. For healthcare systems, they contribute to reduced hospital visits and needlestick injuries, helping manage rising healthcare costs while ensuring consistent and accurate medication delivery for chronic conditions, improving overall patient outcomes.

Need data specifically for your business?Request Custom Research →
Related Reports

Trusted by the world's leading organizations

Weber Shandwick
veolia
Tri
tls
TeamViewer
GE Healthcare
Intel
Proctor and Gamble
ABB
Elkem
Defense Logistics Agency
Amazon